Age at Growth Hormone Therapy Start and First-Year Responsiveness to Growth Hormone Are Major Determinants of Height Outcome in Idiopathic Short Stature

2007 ◽  
Vol 68 (2) ◽  
pp. 53-62 ◽  
Author(s):  
Michael B. Ranke ◽  
Anders Lindberg ◽  
David A. Price ◽  
Feyza Darendeliler ◽  
Kerstin Albertsson-Wikland ◽  
...  
2018 ◽  
Vol 44 (1-2) ◽  
pp. 16-26 ◽  
Author(s):  
Michal Yackobovitch-Gavan ◽  
Galia Gat-Yablonski ◽  
Biana Shtaif ◽  
Shir Hadani ◽  
Shiran Abargil ◽  
...  

2019 ◽  
Vol 70 (2) ◽  
pp. 571-574
Author(s):  
Alin Demetrian ◽  
Smaranda Adelina Preda ◽  
Oana Mariana Cristea ◽  
Carmen Dragomirescu ◽  
Ionela Mihaela Vladu

Idiopathic short stature (ISS) deficiency reflects a major public health issue. In Romania the incidence is 1/3000 - 6000 births, with an increased prevalence in boys. ISS is the condition where the height of a subject is more than -2.5 DS below the height of the population for the population in which it is included, below the mean height for age and sex, but without any nutritional, systemic or chromosomal abnormalities. Significant for children with ISS is that weight is normal at birth and growth hormone levels are normal. This study shows the evolution of the height to normal values specific to the biological age, reaching the normal stature, according to auxological parameters, after growth hormone therapy.


2011 ◽  
Vol 17 (3) ◽  
pp. 218 ◽  
Author(s):  
NagwaAbdallah Ismail ◽  
FatmaAhmed El-Moguy ◽  
SohaM Abd El Dayem ◽  
NermeenSalah Eldin Metwaly ◽  
MonaHassan Hafez ◽  
...  

1998 ◽  
Vol 132 (3) ◽  
pp. 455-460 ◽  
Author(s):  
L.T.M. Rekers-Mombarg ◽  
G.G. Massa ◽  
J.M. Wit ◽  
A.M.C. Matranga ◽  
J.M.H. Buckler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document